Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10995387 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ma T, et al. (2000) Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 14, 2298-313 10995387
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S775-p - NPAT (human) ▲
Orthologous residues
NPAT (human): S775‑p, NPAT (mouse): S771‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
Downstream Regulation
 Effect of modification (process):  transcription, altered
 Comments:  multiple sites deletion mutant

S779-p - NPAT (human) ▲
Orthologous residues
NPAT (human): S779‑p, NPAT (mouse): S773‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
Downstream Regulation
 Effect of modification (process):  transcription, altered
 Comments:  multiple sites deletion mutant

S1100-p - NPAT (human) ▲
Orthologous residues
NPAT (human): S1100‑p, NPAT (mouse): S1096‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
Downstream Regulation
 Effect of modification (process):  transcription, altered
 Comments:  multiple sites deletion mutant

T1270-p - NPAT (human) ▲
Orthologous residues
NPAT (human): T1270‑p, NPAT (mouse): T1264‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK2 (human) microscopy-colocalization, co-immunoprecipitation colocalizes with cyclin E in a cell-cycle dependent manner
Downstream Regulation
 Effect of modification (process):  transcription, altered
 Comments:  multiple sites deletion mutant; phosphorylation of this site is cell-cycle regulated

T1350-p - NPAT (human) ▲
Orthologous residues
NPAT (human): T1350‑p, NPAT (mouse): T1343‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK2 (human) microscopy-colocalization, co-immunoprecipitation colocalizes with cyclin E in a cell-cycle dependent manner
Downstream Regulation
 Effect of modification (process):  transcription, altered
 Comments:  multiple sites deletion mutant; phosphorylation of this site is cell-cycle regulated


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.